Cardiovascular disease in renal transplant recipients

Journal of Renal Care

Volumn 36, Issue SUPPL. 1, 2010, Pages 136-145

  McQuarrie, Emily P ^a   Fellström, Bengt C ^b   Holdaas, Hallvard ^c   Jardine, Alan G ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cardiovascular; Dialysis; Hypertension; Lipids; Mortality; Myocardial infarction; Transplant; Uraemic cardiomyopathy

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; HUMAN; KIDNEY TRANSPLANTATION; MORTALITY; NURSING; PATHOPHYSIOLOGY; PHYSIOLOGY; POSTOPERATIVE COMPLICATION; PRIMARY GRAFT DYSFUNCTION; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SURVIVAL RATE;

CARDIOVASCULAR DISEASES; CAUSE OF DEATH; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PRIMARY GRAFT DYSFUNCTION; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL RATE;

EID: 77952571022     PISSN: 17556678     EISSN: 17556686     Source Type: Journal    
DOI: 10.1111/j.1755-6686.2010.00160.x     Document Type: Article

References (50)

1. Abbott K.C., Hypolite I.O., Hshieh P. et al 2002). Hospitalized congestive heart failure after renal transplantation in the United States. Annals of Epidemiology 12, 115 122. (Pubitemid 34204115)
2. Baigent C., Burbury K. Wheeler D. (2000). Premature cardiovascular disease in chronic renal failure. Lancet 356, 147 152.
3. Balla A. Chobanian M. (2009). New-onset diabetes after transplantation: a review of recent literature. Current Opinion in Organ Transplantation 14, 375 379.
4. Cole E.H., Johnston O., Rose C.L. et al 2008). Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clinical Journal of American Society of Nephrology 3, 814 821.
5. Cosio F.G., Kudva Y. Velde M. (2005). New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney International 67 (6 2415 2421. DIRECT study.
6. Cosio F.G., Pesavento T.E., Pelletier R.P. et al 2002). Patient survival after renal transplantation III: the effects of statins. American Journal of Kidney Diseases 40, 638 643.
7. Fellström B., Holdaas H., Jardine A.G. et al 2005). Assessment of Lescol in Renal Transplantation Study Investigators. Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial. Transplantation 79, 205 212.
8. Fellström B.C., Jardine A.G., Schmieder R.E. et al 2009). AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. The New England Journal of Medicine 360, 1395 1407.
9. Foley R.N., Parfrey P.S., Harnett J.D. et al 1995). The prognostic importance of left ventricular geometry in uremic cardiomyopa-thy. American Journal of Kidney Diseases 5, 2024 2031.
10. Gaston R.S., Kasiske B.L., Fieberg A.M. et al 2009). Use of cardioprotective medications in kidney transplant recipients. American Journal of Transplantation 9, 1811 1815.
11. Heinze G., Mitterbauer C., Regele H. et al 2006). Angiotensin-con-verting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. Journal of the American Society of Nephrology 17, 889 899.
12. Holdaas H., Fellstrom B., Jardine A. et al 2005a). Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361, 2024 2031.
13. Holdaas H., Fellstrom B., Cole E. et al 2005b). Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. American Journal of. Transplantation 5, 2929 2936.
14. Holdaas H., Fellström B., Jardine A.G. et al 2005c). ALERT Study Group. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. Nephrology Dialysis Transplantation 20, 974 980.
15. Holdaas H., Jardine A.G., Wheeler D.C. et al 2001). Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney International 60, 1990 1997.
16. Holdaas H., Kobashigawa J.A., Fellstrom et al 2008). Special transplant populations: transplant recipients. In Clinical Lipidology ed Ballantyne CM pp. 486 499.
17. Jardine A.G., Fellström B., Logan J.O. et al 2005). Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. American Journal of Kidney Diseases 46, 529 536.
18. Jardine A.G., Holdaas H., Fellström B. et al 2004). ALERT Study Investigators. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study. American Journal of Transplantation 4, 988 995.
19. Johnson R.W., Kreis H., Oberbauer R. et al 2001). Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 72, 777 786.
20. Joss N., Staatz C.E., Thomson A.H. et al 2007). Predictors of new onset diabetes after renal transplantation. Clinical Transplantation 21, 136 143.
21. Kasiske B.L., Chakkera H.A. Roel J. (2000b) Explained and unexplained ischemic heart disease risk after renal transplantation. Journal of the American Society of Nephrology 11, 1735 1743.
22. Kasiske B.L., Guijarro C, Massy Z.A. et al 2000a). Cardiovascular disease after renal transplantation. Journal of the American Society of Nephrology 7, 158 165.
23. Kasiske B.L. Klinger D. (2000). Cigarette smoking in renal transplant recipients. Journal of American Society of Nephrology 11, 753 759.
24. Kidney Disease: Improving Global Outcomes (KDIGO) (2009). Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. American Journal of Transplantation 9 (Suppl 3 S1 S155.
25. Kjekshus J., Apetrei E., Barrios V. et al 2007). CORONA Group. Rosuvastatin in older patients with systolic heart failure. The New England Journal of Medicine 357, 2248 2261.
26. Knight S.R. Morris P.J. (2010). Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 89 (1 1 14.
27. Lo R. Hsia H.H. (2008). Ventricular arrhythmias in heart failure patients. Cardiology Clinics 26, 381 403.
28. Manitpisitkul W., McCann E., Lee S. et al 2009). Drug interactions in transplant patients: what everyone should know. Current Opinion in Nephrology Hypertension 18, 404 411.
29. Mark P.B., Johnston N., Groenning B.A. et al 2006). Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney International 69, 1839 1845.
30. Midtvedt K., Ihlen H., Hartmann A. et al 2001). Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: a prospective randomized double-blind study. Transplantation 72, 107 111.
31. Opelz G., Wujciak T. Ritz E. (1998). Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney International 53 (1 217 222.
32. Opelz G., Zeier M., Laux G. et al 2006). No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. Journal of American Society of Nephrology 17, 3257 3262.
33. Paoletti E. Cannella G. (2009). Reducing the risk of left ventricular hypertrophy in kidney transplant recipients: the potential role of mammalian target of rapamycin. Transplantation Proceedings 41, S3 S5.
34. Patel R.K., Oliver S., Mark P.B. et al 2009) Determinants of left ventricular mass and hypertrophy in haemodialysis patients assessed by cardiac magnetic resonance imaging. Clinical Journal of the American Society of Nephrology 4, 1477 1483.
35. Philipp T., Martinez F., Geiger H. et al 2009). Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrology Dialysis Transplantation 25, 967 976.
36. Ramaraj R. (2008). Hypertrophic cardiomyopathy: etiology, diagnosis, and treatment. Cardiology in Review 16, 172 180.
37. Rigatto C., Parfrey P., Foley R. et al 2002). Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease. Journal of American Society of Nephrology 13, 1084 1090.
38. Scandinavian Simvastatin Survival Study (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383 1389.
39. Soveri I., Holdaas H., Jardine A. et al 2006). Renal transplant dysfunction - importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality. Nephrology Dialysis Transplantation 21 (8 2282 2289.
40. Srinivas T.R. Meier-Kriesche H.U. (2008). Minimizing immunosup-pression, an alternative approach to reducing side effects: objectives and interim result. Clinical Journal of the American Society of Nephrology 3, S101 S116.
41. Stewart G.A., Gansevoort R.T., Mark P.B. et al 2005). Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney International 67, 217 226.
42. Tutone V.K., Mark P.B., Stewart G.A. et al 2005). Hypertension, antihypertensive agents and outcomes following renal transplantation. Clinical Transplantation 19, 181 192.
43. Walker B.R. (2007). Glucocorticoids and cardiovascular disease. European Journal of Endocrinology 157, 545 559.
44. Wanner C., Krane V., März W. et al 2009). German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 353, 238 248.
45. Wheatley K., Ives N., Gray R. et al 2009). ASTRAL Investigators, Revascularization versus medical therapy for renal-artery stenosis. The New England Journal of Medicine 361, 1953 1962.
46. Wilkinson A., Davidson J., Dotta F. et al 2005). Guidelines for the treatment and management of new-onset diabetes after transplantation. Clinical Transplantation 19, 291 298.
47. Wissing K.M., Unger P., Ghisdal L. et al 2006). Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation. Transplantation 82, 771 778.
48. Wolfe R.A., Ashby V.B., Milford E.L. et al 1999). Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. The New England Journal of Medicine 341, 1725 1730.
49. Zhang R., Leslie B., Boudreaux J.P. et al 2003). Hypertension after kidney transplantation: impact, pathogenesis and therapy. American Journal of Medicine Science 325, 202 208.
50. Zoccali C. (2006). Traditional and emerging cardiovascular and renal risk factors: an epidemiologic perspective. Kidney International 70, 26 33.